600488.SS
600488.SS
CNE000001840
TIANJIN TIANYAO PHARMACEUTICAL
Loading chart...

Company Profile

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, betamethasone product series, and other hormone precursors. The company provides amino acid raw materials, as well as preparations, including injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, inhalation preparations, and tablets. It also exports its products to the United States, Southeast Asia, Asia, Europe, South America, Africa, and internationally. The company was founded in 1939 and is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. operates as a subsidiary of Tianjin Pharmaceutical Group Co., Ltd.

Related stocks

000597.SZ
000597.SZ • China
NEP.
4.91 CNY
1.05B USD 1Y -10.2%
600422.SS
600422.SS • China
KPC PHARMACEUTICALS INC
8.36 CNY
946.93M USD 1Y -40.3%
688276.SS
688276.SS • China
CHANGCHUN BCHT BIOTECHNOLOGY CO
17.79 CNY
1.1B USD 1Y -19.6%
600252.SS
600252.SS • China
GUANGXI WUZHOU ZHONGHENG GROUP
2.25 CNY
1.07B USD 1Y -17.6%
002038.SZ
002038.SZ • China
SL PHARM
5.76 CNY
885.46M USD 1Y -20.3%
002550.SZ
002550.SZ • China
QIANHONG BIO-PHARMA
6.52 CNY
1.25B USD 1Y -28.4%
000566.SZ
000566.SZ • China
HAINAN HAIYAO
4.71 CNY
914.35M USD 1Y -13.7%
002907.SZ
002907.SZ • China
PHARSCIN PHARMA
15.44 CNY
964.79M USD 1Y -4.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
40.7% p.a.
Max Drawdown (5Y)
-45.7%
Sharpe Ratio (5Y)
0.13
Beta Factor
-0.07
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 107.8 (Elevated multiple compression risk)
Elevated Short-Term Volatility: 3Y volatility (47.1%) is noticeably higher than the 5Y average (40.7%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -52.5% in the extended horizon.
ende